x min read

Advanced Medical Isotope Corp (OTCMKTS:ADMD) Is Today's Biotech Focus

Advanced Medical Isotope Corp (OTCMKTS:ADMD) Is Today's Biotech Focus
Written by
Alex Carlson
Published on
June 2, 2016
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

Advanced Medical Isotope Corp (OTCMKTS:ADMD) has quickly emerged as a microcap runner on the OTC Markets. The company has become a favorite on the iHub message boards and one which a lot of traders are talking about. ADMD has also captured the interest of the Wealthy Biotech Trader and the newsletter has been recommending the stock to its readers.ADMD describes itself as "a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the company will evaluate its alternatives before finalizing its plans." Chairman and CEO James Katzaroff recently said:

"With the recent filing of our 10K annual report, we now look forward to presenting to existing shareholders and new investors the significant progress in our capital restructuring plan as well as our regulatory and commercialization roadmap for 2016. We are very pleased with the results of our efforts to improve our balance sheet during 2015. We continue with our unshakable commitment to normalize our capital structure, having reduced our liabilities by over $11 million in 2015 and to continue our efforts commercialize our Y-90 RadioGel(TM) device and IsoPet Solutions."

In August 2015, ADMD announced a partnership with IsoTherapeutics Group, LLC to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel(TM) device. Following the successful completion of the first stage of tech transfer, manufacturing and in vitro testing in late 2015, ADMD and IsoTherapeutics Group have been focusing on additional in vitro and in vivo testing.In connection with the efforts related to ADMD's Y-90 RadioGel(TM) device, product will also be manufactured for the purposes of further product characterization testing, in vivo studies and data collection to support the company's FDA filing. ADMD is preparing for in vivo testing of the product in pancreatic tumors lines to evaluate the bio-distribution and therapeutic effect. ADMD intends to seek classification and clearance as a class II medical device through a de novo application.ADMD anticipates shipping product within the next 30 days to Washington State University for a study that is actively recruiting companion cats for the treatment of feline sarcoma. The biotech company is the commercialization partner under a $250,000 grant awarded to Washington State University by Washington State's Life Sciences Discovery Fund for this study. Chairman and CEO James Katzaroff said:

"We have been rapidly progressing in the product development for the human and veterinary markets. We are very pleased with the progress to date and are excited to provide our product for the initial treatments in companion animals."

The veterinary market has big potential for ADMD. The company's IsoPet Solutions division will focus on bringing ADMD’s yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers. Consider that there are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions’ goal is to establish the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. ADMD expects the initial treatments to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.Currently trading with a market cap of $12.4 million, shares are up slightly from where we covered them back in April. For the period ending December 2015, ADMD reported $620 thousand in net income, zero revenues, $179 thousand in cash, $254 thousand in total assets, and $9.9 million in liabilities. We will be updating Insider Financial as soon as we know more. For continuing coverage on ADMD, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in ADMD and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.